Monte Rosa Therapeutics(GLUE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

GLUE Monte Rosa Therapeutics

Post-Mkt 06-17 19:29:19 EDT

18.41

+0.65

+3.66%

盘后18.41

+0.000.00%

16:10 EDT

High19.22	Low17.93	Vol1.18M
Open17.93	D1 Closing17.76	Amplitude7.29%
Mkt Cap1.55B	Tradable Cap1.13B	Total Shares84.38M
T/O22.01M	T/O Rate1.92%	Tradable Shares61.57M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"GLUE","market":"US","secType":"STK","nameCN":"Monte Rosa Therapeutics","latestPrice":18.41,"timestamp":1781726400000,"preClose":17.76,"halted":0,"volume":1184533,"hourTrading":{"tag":"盘后","latestPrice":18.41,"preClose":18.41,"latestTime":"16:10 EDT","volume":20508,"amount":377546.886396,"timestamp":1781727005126,"change":0,"changeRate":0,"amplitude":0.007061},"delay":0,"changeRate":0.03659909909909902,"floatShares":61574700,"shares":84382573,"eps":-1.495445,"marketStatus":"Post-Mkt","change":0.65,"latestTime":"06-17 19:29:19 EDT","open":17.925,"high":19.22,"low":17.925,"amount":22009665,"amplitude":0.072917,"askPrice":21.39,"askSize":100,"bidPrice":18.28,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-1.495445,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1781740800000},"marketStatusCode":4,"adr":0,"listingDate":1624507200000,"exchange":"NASDAQ","adjPreClose":17.76,"preHourTrading":{"tag":"盘前","latestPrice":17.95,"preClose":17.76,"latestTime":"09:27 EDT","volume":1643,"amount":29369.47936,"timestamp":1781702842390,"change":0.19,"changeRate":0.010698,"amplitude":0.0625},"postHourTrading":{"tag":"盘后","latestPrice":18.41,"preClose":18.41,"latestTime":"16:10 EDT","volume":20508,"amount":377546.886396,"timestamp":1781727005126,"change":0,"changeRate":0,"amplitude":0.007061},"volumeRatio":1.210343,"impliedVol":0.8585,"impliedVolPercentile":0.4622},"requestUrl":"/m/hq/s/GLUE/tweets","defaultTab":"tweets","newsList":[{"id":"2642316432","title":"Monte Rosa Therapeutics held annual shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2642316432","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642316432?lang=en_us&edition=fundamental","pubTime":"2026-06-12 04:01","pubTimestamp":1781208117,"startTime":"0","endTime":"0","summary":"Monte Rosa Therapeutics held its annual shareholder meeting on June 11, 2026.Shareholders elected Andrew Schiff, Chandra P. Leo, Anthony Manning as Class II directors for terms expiring at the 2029 annual meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Monte Rosa Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 11, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260611:nNDL15Rn7t:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","GLUE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640232369","title":"Monte Rosa CEO Markus Warmuth sells USD 106,197 of common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2640232369","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640232369?lang=en_us&edition=fundamental","pubTime":"2026-06-03 04:06","pubTimestamp":1780430803,"startTime":"0","endTime":"0","summary":"Monte Rosa Therapeutics President and CEO Markus Warmuth sold 5,466 common shares on June 1.Shares sold at weighted average prices of $19.41, $19.73.Directly held stake fell to 594,538 common shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Monte Rosa Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 02, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nNDLc5RKlT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Monte Rosa CEO Markus Warmuth sells USD 106,197 of common shares","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GLUE","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640927923","title":"Monte Rosa grants inducement awards to new hires, including options for 20,050 shares at USD 19.67","url":"https://stock-news.laohu8.com/highlight/detail?id=2640927923","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640927923?lang=en_us&edition=fundamental","pubTime":"2026-06-03 04:01","pubTimestamp":1780430514,"startTime":"0","endTime":"0","summary":"Monte Rosa Therapeutics granted inducement equity awards to four newly hired non-executive employees under its 2026 Inducement Plan.Awards include non-qualified stock options for 20,050 shares at an exercise price of USD 19.67, based on the June 1 close.Options vest 25% after one year, then monthly over three years; 4,400 restricted stock units vest 25% annually over four years.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nNDL31mCpw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","BK4588","NDAQ","SG9999014021.USD","SG9999014005.SGD","BK4139","IE00BGHQF748.EUR","BK4539","IE00BKPKM429.USD","IE00B3QW5Z07.USD","GLUE","IE00BN0W2V16.EUR","LU2210150020.SGD","LU0314104364.USD","IE00BN0W2W23.USD","IE00B64PRP62.GBP","LU2210149790.SGD","BK4585","IE00BN0W2T93.GBP","SG9999014039.USD","LU2095319765.USD","SG9999014013.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640594964","title":"Monte Rosa Therapeutics CSO Sharon Townson disposes of common shares worth $119,220","url":"https://stock-news.laohu8.com/highlight/detail?id=2640594964","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640594964?lang=en_us&edition=fundamental","pubTime":"2026-06-02 04:07","pubTimestamp":1780344436,"startTime":"0","endTime":"0","summary":"Monte Rosa Therapeutics Chief Scientific Officer Sharon Townson sold 6,000 common shares on May 29 at USD 19.87.Townson also exercised stock options for 6,000 shares at USD 6.14.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Monte Rosa Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 01, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nNDL6s9qh0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Monte Rosa Therapeutics CSO Sharon Townson disposes of common shares worth $119,220","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GLUE","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640968764","title":"Monte Rosa posts corporate deck spotlighting molecular glue degrader pipeline for immunology, inflammation and cancer targets","url":"https://stock-news.laohu8.com/highlight/detail?id=2640968764","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640968764?lang=en_us&edition=fundamental","pubTime":"2026-06-01 23:27","pubTimestamp":1780327653,"startTime":"0","endTime":"0","summary":"Monte Rosa posts corporate deck spotlighting molecular glue degrader pipeline for immunology, inflammation and cancer targets. Monte Rosa outlined three clinical molecular glue degrader programs, with Phase 2 trials expected to start in 2026.Pipeline focus: MRT-6160  for immune-mediated diseases, MRT-8102  for IL-1β/NLRP3-driven inflammation, MRT-2359  for castration-resistant prostate cancer.Phase 2 initiation for MRT-6160 targeted for Q3 2026; MRT-8102 Phase 1 data and Phase 2 start targeted for H2 2026.Collaboration receipts totaled about $350 million over the past three years, with potential for more than $400 million over the next 24 months.Cash runway projected into 2029; additional wholly owned IND filings expected over the next two years, including a CCNE1 MGD in H2 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nNDL1VzvW8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","GLUE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639142616","title":"Monte Rosa COO Jennifer Champoux disposes of 2,175 shares for $43,500","url":"https://stock-news.laohu8.com/highlight/detail?id=2639142616","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639142616?lang=en_us&edition=fundamental","pubTime":"2026-05-29 07:11","pubTimestamp":1780009880,"startTime":"0","endTime":"0","summary":"Monte Rosa Therapeutics COO Jennifer Champoux sold 2,175 shares at USD 20 on May 27, 2026.The sale followed the exercise of 2,175 stock options at USD 3.98.Champoux ended the day with 62,371 shares of common stock.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Monte Rosa Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 28, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nNDL72phgx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Monte Rosa COO Jennifer Champoux disposes of 2,175 shares for $43,500","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","GLUE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638540678","title":"Monte Rosa COO Jennifer Champoux sells 2,176 common shares worth $41,344","url":"https://stock-news.laohu8.com/highlight/detail?id=2638540678","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638540678?lang=en_us&edition=fundamental","pubTime":"2026-05-27 04:06","pubTimestamp":1779825962,"startTime":"0","endTime":"0","summary":"Monte Rosa Therapeutics COO Jennifer Champoux sold 2,176 shares on May 22 at USD 19, cutting her stake to 62,371 shares.The sale followed the exercise of stock options for 2,176 shares at USD 3.98 on the same day.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Monte Rosa Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 26, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260526:nNDL42qN4b:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Monte Rosa COO Jennifer Champoux sells 2,176 common shares worth $41,344","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","GLUE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637323620","title":"Insider Shake-Up at Monte Rosa Therapeutics Sparks Investor Buzz","url":"https://stock-news.laohu8.com/highlight/detail?id=2637323620","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637323620?lang=en_us&edition=fundamental","pubTime":"2026-05-23 10:02","pubTimestamp":1779501756,"startTime":"0","endTime":"0","summary":"New insider activity at Monte Rosa Therapeutics ( ($GLUE) ) has taken place on May 22, 2026. Director Anthony M. Manning of Monte Rosa Therapeutics...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/insider-shake-up-at-monte-rosa-therapeutics-sparks-investor-buzz-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/insider-shake-up-at-monte-rosa-therapeutics-sparks-investor-buzz-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","GLUE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637707341","title":"Monte Rosa director Anthony Manning disposes 10,000 shares worth $180,100","url":"https://stock-news.laohu8.com/highlight/detail?id=2637707341","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637707341?lang=en_us&edition=fundamental","pubTime":"2026-05-23 04:06","pubTimestamp":1779480381,"startTime":"0","endTime":"0","summary":"Monte Rosa Therapeutics director Anthony M. Manning sold 10,000 common shares on May 21, 2026 at USD 18.01, cutting his direct stake to zero.The sale followed the exercise of a stock option for 10,000 shares at USD 4.16 on the same day.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Monte Rosa Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 22, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260522:nNDL3839P3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Monte Rosa director Anthony Manning disposes 10,000 shares worth $180,100","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","GLUE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636849692","title":"Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2636849692","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636849692?lang=en_us&edition=fundamental","pubTime":"2026-05-20 19:00","pubTimestamp":1779274800,"startTime":"0","endTime":"0","summary":"BOSTON, May  20, 2026  (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today an","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/20/3298320/0/en/Monte-Rosa-Therapeutics-to-Participate-in-Upcoming-Investor-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GLUE","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634234822","title":"Monte Rosa Therapeutics Is Maintained at Overweight by JP Morgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2634234822","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634234822?lang=en_us&edition=fundamental","pubTime":"2026-05-12 03:20","pubTimestamp":1778527200,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/GLUE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 11, 2026 15:20 ET (19:20 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GLUE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633173180","title":"Analysts Offer Insights on Healthcare Companies: Foghorn Therapeutics (FHTX) and Monte Rosa Therapeutics (GLUE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2633173180","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633173180?lang=en_us&edition=fundamental","pubTime":"2026-05-08 03:20","pubTimestamp":1778181622,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Foghorn Therapeutics (FHTX) and Monte Rosa Therapeut...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-foghorn-therapeutics-fhtx-and-monte-rosa-therapeutics-glue-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-foghorn-therapeutics-fhtx-and-monte-rosa-therapeutics-glue-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GLUE","BK4581","FHTX","LU0128526141.USD","LU0029874061.USD","BK4139","XLV","LABU","BK4137","BK4539","BK4585","XBI","BK4588","HCSG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633124245","title":"Monte Rosa Therapeutics reports Q1 revenue $4.21M, consensus $11.39M","url":"https://stock-news.laohu8.com/highlight/detail?id=2633124245","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633124245?lang=en_us&edition=fundamental","pubTime":"2026-05-08 00:19","pubTimestamp":1778170794,"startTime":"0","endTime":"0","summary":"“We continue to make excellent progress advancing multiple programs through the clinic, with all three of our clinical-stage programs approaching P...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/monte-rosa-therapeutics-reports-q1-revenue-4-21m-consensus-11-39m-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/monte-rosa-therapeutics-reports-q1-revenue-4-21m-consensus-11-39m-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GLUE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633128538","title":"Monte Rosa Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2633128538","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633128538?lang=en_us&edition=fundamental","pubTime":"2026-05-07 21:23","pubTimestamp":1778160202,"startTime":"0","endTime":"0","summary":"Monte Rosa Therapeutics Inc reports results for the quarter ended March 31 - Earnings SummaryMonte Rosa Therapeutics Inc GLUE.OQ reported a quarterly adjusted loss of 45 cents per share for the quarte","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nL8N41K1OS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GLUE","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633146212","title":"Monte Rosa Therapeutics Q1 collaboration revenue drops 95%","url":"https://stock-news.laohu8.com/highlight/detail?id=2633146212","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633146212?lang=en_us&edition=fundamental","pubTime":"2026-05-07 19:28","pubTimestamp":1778153332,"startTime":"0","endTime":"0","summary":"Monte Rosa Therapeutics Q1 collaboration revenue drops 95%OverviewUS biotech firm's Q1 collaboration revenue fell 95% yr/yrCompany posted Q1 net loss after prior-year profitCash position rose after $3","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nL1N41K0LO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","GLUE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633462331","title":"Monte Rosa publishes investor presentation on molecular glue degrader pipeline and Phase 2 plans","url":"https://stock-news.laohu8.com/highlight/detail?id=2633462331","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633462331?lang=en_us&edition=fundamental","pubTime":"2026-05-07 19:25","pubTimestamp":1778153159,"startTime":"0","endTime":"0","summary":"Monte Rosa outlined plans to start Phase 2 trials in 2026 for three molecular glue degrader programs, including VAV1 degrader MRT-6160, NEK7 degrader MRT-8102, and GSPT1 degrader MRT-2359.Pipeline update flagged Phase 2 initiation for MRT-8102 in Q3 2026, with Phase 1 data for MRT-2359 followed by Phase 2 initiation in H2 2026.Additional wholly owned IND submissions targeted for H2 2026, including CCNE1 MGD, with further INDs anticipated over next two years.Collaboration economics highlighted USD 350 million received in collaboration payments over last three years, with potential for more than USD 400 million over next 24 months.Balance sheet commentary pointed to cash runway into 2029.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mo","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nNDL7sXQ0g:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GLUE","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633145975","title":"Monte Rosa Q1 FY26 net loss widens to $44.5 million; revenue falls to $4.2 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633145975","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633145975?lang=en_us&edition=fundamental","pubTime":"2026-05-07 19:03","pubTimestamp":1778151805,"startTime":"0","endTime":"0","summary":"Monte Rosa Therapeutics posted a net loss of $44.5 million for first-quarter 2026, swinging from net income of $46.9 million a year earlier, as revenue fell to $4.2 million from $84.9 million.R&D expenses climbed to $44.1 million from $32.2 million, while G&A costs rose to $10.2 million from $8.7 million.Cash, cash equivalents, restricted cash, and marketable securities totaled $671 million at March 31, up from $382.1 million at Dec. 31, following a $345 million public offering in January.Phase 2 starts planned for MRT-8102 in H2 2026, while MODeFIRe-1 Phase 2 for MRT-2359 with apalutamide in mCRPC with AR mutations is slated for Q3 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nNDLjvK1p:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","BK4588","NDAQ","SG9999014021.USD","SG9999014005.SGD","BK4139","IE00BGHQF748.EUR","BK4539","IE00BKPKM429.USD","IE00B3QW5Z07.USD","GLUE","IE00BN0W2V16.EUR","LU2210150020.SGD","LU0314104364.USD","IE00BN0W2W23.USD","IE00B64PRP62.GBP","LU2210149790.SGD","BK4585","IE00BN0W2T93.GBP","SG9999014039.USD","LU2095319765.USD","SG9999014013.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633432301","title":"BRIEF-Monte Rosa Therapeutics Q1 Net Income USD -44.503 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633432301","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633432301?lang=en_us&edition=fundamental","pubTime":"2026-05-07 19:00","pubTimestamp":1778151649,"startTime":"0","endTime":"0","summary":"BRIEF-Monte Rosa Therapeutics Q1 Net Income USD -44.503 Million\n\n\nMay 07 (Reuters) - Monte Rosa Therapeutics Q1 operating income USD -50.034 million.\n\nQ1 collaboration revenue USD 4.21 million\nQ1 operating expenses USD 54.244 million","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nPLX1A261F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GLUE","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633143976","title":"Monte Rosa Therapeutics Q1 Operating Expenses USD 54.244 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633143976","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633143976?lang=en_us&edition=fundamental","pubTime":"2026-05-07 19:00","pubTimestamp":1778151604,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nPLX1A261F:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","BK4139","GLUE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633143165","title":"Monte Rosa Therapeutics Q1 Operating Income USD -50.034 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633143165","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633143165?lang=en_us&edition=fundamental","pubTime":"2026-05-07 19:00","pubTimestamp":1778151604,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nPLX1A261F:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","GLUE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.monterosatx.com","stockEarnings":[{"period":"1week","weight":0.0692},{"period":"1month","weight":-0.0215},{"period":"3month","weight":0.1269},{"period":"6month","weight":0.1219},{"period":"1year","weight":2.6846},{"period":"ytd","weight":0.1327}],"compareEarnings":[{"period":"1week","weight":0.018},{"period":"1month","weight":0.0151},{"period":"3month","weight":0.1344},{"period":"6month","weight":0.1092},{"period":"1year","weight":0.245},{"period":"ytd","weight":0.1003}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.040424},{"month":2,"riseRate":0.4,"avgChangeRate":-0.031875},{"month":3,"riseRate":0.4,"avgChangeRate":0.028615},{"month":4,"riseRate":0.4,"avgChangeRate":-0.132561},{"month":5,"riseRate":0.4,"avgChangeRate":-0.001871},{"month":6,"riseRate":0.4,"avgChangeRate":0.013064},{"month":7,"riseRate":0.8,"avgChangeRate":0.071272},{"month":8,"riseRate":0.4,"avgChangeRate":0.098753},{"month":9,"riseRate":0.4,"avgChangeRate":-0.025082},{"month":10,"riseRate":0.8,"avgChangeRate":0.245263},{"month":11,"riseRate":0.4,"avgChangeRate":0.027512},{"month":12,"riseRate":0.4,"avgChangeRate":0.082538}],"exchange":"NASDAQ","name":"Monte Rosa Therapeutics","nameEN":"Monte Rosa Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Monte Rosa Therapeutics(GLUE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Monte Rosa Therapeutics(GLUE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Monte Rosa Therapeutics,GLUE,Monte Rosa Therapeutics股票,Monte Rosa Therapeutics股票老虎,Monte Rosa Therapeutics股票老虎国际,Monte Rosa Therapeutics行情,Monte Rosa Therapeutics股票行情,Monte Rosa Therapeutics股价,Monte Rosa Therapeutics股市,Monte Rosa Therapeutics股票价格,Monte Rosa Therapeutics股票交易,Monte Rosa Therapeutics股票购买,Monte Rosa Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Monte Rosa Therapeutics(GLUE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Monte Rosa Therapeutics(GLUE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}